azole resistance – Page 2

Emerging antifungal resistance in Trichophyton mentagrophytes: insights from susceptibility profiling and genetic mutation analysis

mycolabadmin

This study examined how common skin fungal infections caused by Trichophyton species are becoming resistant to standard antifungal treatments. Researchers tested 131 fungal isolates from China and analyzed their resistance genes to understand why some strains no longer respond to terbinafine and other antifungal drugs. They found that certain genetic mutations, particularly in the SQLE gene, make these fungi resistant to treatment and that different species have different resistance patterns. These findings help doctors better choose treatments and guide the development of new antifungal medications.

Candida blankii: The Difficult Capture of a Fungus With Pathogenic Potential

mycolabadmin

Candida blankii is a rare fungal pathogen that is increasingly being found in hospital patients’ bloodstreams and respiratory tracts. The organism is difficult to identify using standard laboratory tests, which can delay diagnosis and treatment. This case report describes two adult patients with C. blankii infections and highlights the challenges in identifying this emerging pathogen and its resistance to common antifungal medications.

Investigation of the antifungal activity of panobinostat, tamoxifen, and miltefosine alone and in combination with some conventional antifungal drugs against fluconazole-resistant Candida species

mycolabadmin

Researchers tested whether three cancer drugs (panobinostat, tamoxifen, and miltefosine) could enhance the effectiveness of common antifungal medications against drug-resistant yeast infections. When combined with antifungals, some of these cancer drugs showed promise in killing resistant Candida species, though the effectiveness varied depending on which type of yeast was being treated. These findings suggest that combination therapies using already-approved drugs could help treat difficult fungal infections in cancer patients.

Prevalence of Candida and Other Yeasts in Vulvovaginal Infections during Pregnancy: A 10-Year Serbian Survey

mycolabadmin

This study examined yeast infections in pregnant Serbian women over 10 years, finding that nearly half had positive tests. While Candida albicans was most common, many other yeast species were also identified, some of which are resistant to common antifungal medications. Using advanced laboratory techniques (MALDI-TOF MS), researchers found more accurate identification was possible, which is important since different yeasts require different treatments, especially during pregnancy when some medications can harm the baby.

In Vitro Activity of Nitroxoline (5-Nitro-8-Hydroxyquinoline) Against Aspergillus Species

mycolabadmin

Researchers tested an old antibiotic called nitroxoline against dangerous fungal infections caused by Aspergillus species. The drug works by removing important minerals like zinc that these fungi need to survive. Testing showed nitroxoline was very effective against these fungi, even against strains that had developed resistance to modern antifungal drugs. This suggests nitroxoline could potentially be repurposed as a new treatment option for serious fungal infections.

Clinical aspects and recent advances in fungal diseases impacting human health

mycolabadmin

Fungal infections affect over a billion people worldwide and are becoming harder to treat due to growing resistance to antifungal medications. The review discusses major challenges in detecting and treating these infections, including difficulty in diagnosis and limited awareness among healthcare providers. New antifungal drugs are being developed and approved to address these challenges, but a comprehensive approach involving better awareness, improved testing, and responsible medication use is needed.

Evaluation of Antifungal Activity Against Candida albicans Isolates From HIV-Positive Patients with Oral Candidiasis in a Major Referral Hospital, West Java, Indonesia

mycolabadmin

This study examined fungal infections in HIV-positive patients suffering from oral candidiasis (mouth thrush) in Indonesia. Researchers identified the types of Candida fungi present and tested their resistance to four common antifungal medications. Most patients had Candida albicans, and while these fungi generally responded well to newer antifungal drugs like voriconazole and fluconazole, some showed resistance, particularly to fluconazole, suggesting the need for careful testing before prescribing treatment.

Pyrvinium Pamoate Synergizes with Azoles in vitro and in vivo to Exert Antifungal Efficacy Against Candida auris and Other Candida Species

mycolabadmin

Researchers tested a combination of an old antiparasitic drug called pyrvinium pamoate with common antifungal medications called azoles against dangerous drug-resistant fungal infections. While pyrvinium pamoate alone was not very effective, when combined with azoles it significantly improved the treatment of Candida auris infections. Tests in insect larvae showed that the combination improved survival rates better than using azoles alone, suggesting a promising new treatment approach for serious fungal infections.

Leveraging synthetic genetic array screening to identify therapeutic targets and inhibitors for combatting azole resistance in Candida glabrata

mycolabadmin

Candida glabrata is a dangerous fungus causing serious infections that is becoming resistant to antifungal drugs. Researchers used a genetic screening technique to find genes that interact with drug resistance mutations and identified methotrexate (a drug already used for arthritis) as a potential partner for fluconazole treatment. When combined, these drugs work better together against resistant strains of the fungus, offering hope for treating these stubborn infections.

Caspofungin therapy in prosthetic valve endocarditis and candidemia due to itraconazole-resistant Candida glabrata (Nakaseomyces glabratus): A case report

mycolabadmin

A 13-year-old boy developed a serious fungal infection on his replacement heart valve after recent surgery. The fungal infection was caused by a type of yeast called Candida glabrata that was resistant to the initial antifungal medication. After testing revealed resistance and biofilm formation, doctors switched to caspofungin, a stronger antifungal drug, and the patient recovered successfully.

Research Keyword: azole resistance